<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Entecavir: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Entecavir: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Entecavir: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8816" href="/d/html/8816.html" rel="external">see "Entecavir: Drug information"</a> and <a class="drug drug_patient" data-topicid="11346" href="/d/html/11346.html" rel="external">see "Entecavir: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708732"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Severe acute exacerbations of hepatitis B:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued antihepatitis B therapy, including entecavir. Closely monitor hepatic function with clinical and laboratory follow-up for at least several months in patients who discontinue antihepatitis B therapy. If appropriate, initiation of antihepatitis B therapy may be warranted.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">HIV and chronic hepatitis B virus coinfection:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Limited clinical experience suggests there is a potential for the development of resistance to HIV nucleoside reverse transcriptase inhibitors if entecavir is used to treat chronic hepatitis B virus (HBV) infection in patients with HIV infection not being treated. Therapy with entecavir is not recommended for HIV/HBV coinfected patients who are not also receiving antiretroviral therapy.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lactic acidosis and hepatomegaly:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogue inhibitors alone or in combination with antiretrovirals.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F165232"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Baraclude</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866734"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACCEL-Entecavir;</li>
<li>APO-Entecavir;</li>
<li>Auro-Entecavir;</li>
<li>Baraclude;</li>
<li>JAMP-Entecavir;</li>
<li>MINT-Entecavir;</li>
<li>PMS-Entecavir</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1010948"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F165239"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Oral tablets and solution may be used interchangeably on a mg:mg basis.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9203ca82-591f-48b9-85f3-5262945663e6">Chronic hepatitis B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic hepatitis B (HBV):</b> Oral: <b>Note:</b> Optimal duration of treatment not established for nucleoside analogs, a minimum of 12 months and typically longer required; consolidation therapy of at least 6 months after seroconversion and complete viral suppression has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20890947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20890947'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 2 to &lt;16 years with compensated liver diseases:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment naive:</i></p>
<p style="text-indent:-2em;margin-left:8em;">10 to 11 kg: 0.15 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;11 to 14 kg: 0.2 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;14 to 17 kg: 0.25 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;17 to 20 kg: 0.3 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;20 to 23 kg: 0.35 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;23 to 26 kg: 0.4 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;26 to 30 kg: 0.45 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;30 kg: 0.5 mg oral solution or tablet once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Lamivudine-experienced (ie, &gt;12 weeks of prior lamivudine therapy):</i></p>
<p style="text-indent:-2em;margin-left:8em;">10 to 11 kg: 0.3 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;11 to 14 kg: 0.4 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;14 to 17 kg: 0.5 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;17 to 20 kg: 0.6 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;20 to 23 kg: 0.7 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;23 to 26 kg: 0.8 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;26 to 30 kg: 0.9 mg oral solution once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;30 kg: 1 mg oral solution or tablet once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥16 years:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Nucleoside treatment naive with compensated liver disease:</i> 0.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Lamivudine-refractory or known lamivudine or telbivudine-resistant mutations:</i> 1 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7ae1cb49-6683-4dd1-be2c-35b64903a51a">Hepatitis B virus reinfection prophylaxis, post liver transplant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatitis B virus reinfection prophylaxis, post liver transplant (with or without HBIG):</b> Limited data available: Adolescents ≥16 years: Oral: 1 mg once daily has been reported in an open-label trial of 65 patients (age range: 16 years and older); however, a lower dose of 0.5 mg once daily has also been used in adult patients (age range: 23 to 65 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21762659','lexi-content-ref-23788462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21762659','lexi-content-ref-23788462'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b7fea8da-9c8f-4185-afaf-b053467721b0">HIV/Hepatitis B virus coinfection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV/Hepatitis B virus coinfection:</b> Limited data available: <b>Note: </b>Only recommended in patients who cannot take tenofovir; must be used in addition to a fully suppressive antiretroviral therapy regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DHHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DHHS.1'])">Ref</a></span>): Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nucleoside treatment naive:</i> Adolescents: 0.5 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DHHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DHHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lamivudine-refractory or -resistant with decompensated liver disease:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Children 12 years of age: 0.5 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DHHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DHHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: 1 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DHHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DHHS.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51108473"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; insufficient data to recommend a specific dose adjustment in pediatric patients with renal impairment; a reduction in the dose or an increase in the dosing interval similar to adjustments for adults should be considered.</p></div>
<div class="block dohp drugH1Div" id="F51108474"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥ 2 years and Adolescents: No adjustment necessary.</p></div>
<div class="block doa drugH1Div" id="F165233"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8816" href="/d/html/8816.html" rel="external">see "Entecavir: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7893f6f0-d643-4885-92a5-9e388425083f">Hepatitis B virus infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatitis B virus infection, treatment:</b> Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Nucleoside-treatment naive, compensated liver disease: 0.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Decompensated liver disease: 1 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Treatment duration (AASLD practice guidelines):</i> Treatment duration for nucleos(t)ide analog-based therapy (eg, entecavir) is variable and influenced by HBeAg status, duration of hepatitis B virus (HBV) suppression, and presence of cirrhosis/decompensation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients <i>without</i> cirrhosis:</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatitis B e antigen (HBeAg) positive immune-active chronic hepatitis: Treat until HBeAg seroconversion; after seroconversion, prolonged consolidation therapy is often required in patients treated with nucleos(t)ide analogues to prevent hepatitis flares. Optimal duration is unknown; however, consolidation therapy is generally a minimum of 12 months of persistently normal ALT and undetectable serum HBV DNA levels after HBeAg seroconversion.</p>
<p style="text-indent:-2em;margin-left:6em;">HBeAg-negative immune-active chronic hepatitis: Indefinite antiviral therapy is suggested unless there is competing rationale for discontinuation (risk/benefit decision); treatment discontinuation may be considered in patients with loss of HBsAg; however, there is insufficient evidence to guide decisions in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with<i> compensated </i>cirrhosis:</p>
<p style="text-indent:-2em;margin-left:6em;">HBeAg-positive immune-active chronic hepatitis: In patients who seroconvert on therapy, continue antiviral therapy indefinitely due to concerns with decompensation and death, unless there is a strong competing rationale for discontinuation.</p>
<p style="text-indent:-2em;margin-left:6em;">HBeAg-negative immune-active chronic hepatitis: Treatment discontinuation is not recommended due to potential for decompensation and death (limited data).</p>
<p style="text-indent:-2em;margin-left:4em;">Patients with <i>decompensated</i> cirrhosis: Individuals with decompensated cirrhosis should receive indefinite therapy regardless of HBV DNA level, HBeAg status, or ALT level.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Viral breakthrough (AASLD practice guidelines):</i> Patients with confirmed viral breakthrough (HBV DNA ≥100 IU/mL with previously undetectable levels [&lt;10 IU/mL] or &gt;1 log increase in HBV DNA) should either be switched to an alternative antiviral monotherapy agent with a high genetic barrier to resistance <b>or</b> receive a second antiviral agent with a complementary resistance profile; consult current clinical practice guidelines for recommended agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9713710c-c4f1-4c46-8ae6-f245de5b451e">Hepatitis B virus reactivation prophylaxis, immunocompromised patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatitis B virus reactivation prophylaxis, immunocompromised patients (off-label use):</b> Oral: 0.5 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29405329','lexi-content-ref-23522150','lexi-content-ref-25514302','lexi-content-ref-21054683','lexi-content-ref-27450506']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29405329','lexi-content-ref-23522150','lexi-content-ref-25514302','lexi-content-ref-21054683','lexi-content-ref-27450506'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7ae1cb49-6683-4dd1-be2c-35b64903a51a">Hepatitis B virus reinfection prophylaxis, post liver transplant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatitis B virus reinfection prophylaxis, post liver transplant (with or without hepatitis B immune globulin) (off-label use):</b> Oral: 0.5 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28370215']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28370215'])">Ref</a></span>) or 1 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23788462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23788462'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990807"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: Note: </b>Daily-dosage regimen preferred.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to &lt;50 mL/minute: Administer 50% of usual indication-specific dose daily. Alternatively, administer the usual indication-specific dose every 48 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to &lt;30 mL/minute: Administer 30% of usual indication-specific dose daily. Alternatively, administer the usual indication-specific dose every 72 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Administer 10% of usual indication-specific dose daily. Alternatively, administer the usual indication-specific dose every 7 days.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (13%): Administer 10% of usual indication-specific dose daily. Alternatively, administer usual indication-specific dose every 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31260579','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31260579','lexi-content-ref-Manu.1'])">Ref</a></span>). When scheduled dose falls on a dialysis day, administer after hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not significantly dialyzed (0.3% over 7 days): Administer 10% of usual indication-specific dose daily. Alternatively, administer usual indication-specific dose every 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">No data available in patients on CRRT; because significant clearance is unlikely (large V<sub>d</sub>, low intermittent dialysis clearance), may consider administering 10% of usual indication-specific dose daily. Alternatively, administer usual indication-specific dose every 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">No data available in patients on PIRRT; because significant clearance is unlikely (large V<sub>d</sub>, low intermittent dialysis clearance), may consider administering 10% of usual indication-specific dose daily. Alternatively, administer usual indication-specific dose every 7 days. When scheduled dose falls on a PIRRT session day, administer after PIRRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988007"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">No dosage adjustment necessary.</p></div>
<div class="block adr drugH1Div" id="F165210"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported with adult patients, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hepatic: Increased serum alanine aminotransferase (&gt;5 x ULN: 11% to 12%; &gt;10 x ULN and &gt;2 x baseline: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (children and adolescents: &gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Glycosuria (4%), hyperglycemia (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (children and adolescents: &gt;1%), diarrhea (children and adolescents: &gt;1%; adults: ≤1%), dyspepsia (≤1%), increased serum lipase (7%), nausea (children and adolescents: &gt;1%; adults: &lt;1%), vomiting (children and adolescents: &gt;1%; adults: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (1% to 3%), headache (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, drowsiness, insomnia</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Exacerbation of hepatitis B (severe, acute, with discontinuation)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Lactic acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Malignant neoplasm</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatocellular neoplasm, hepatomegaly with steatosis, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Macular edema (Muqit 2011)</p></div>
<div class="block coi drugH1Div" id="F165220"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to entecavir or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F165208"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactic acidosis/hepatomegaly: <b>[US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with nucleoside analogue inhibitors;</b> use with caution in patients with risk factors for liver disease (risk may be increased with female gender, decompensated liver disease, obesity, or prolonged nucleoside inhibitor exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Chronic hepatitis B: <b>[US Boxed Warning]: Severe, acute exacerbation of hepatitis B may occur upon discontinuation of antihepatitis B therapy, including entecavir. Monitor liver function for at least several months after stopping treatment; reinitiation of antihepatitis B therapy may be required.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• HIV: <b>[US Boxed Warning]: May cause the development of HIV resistance in chronic hepatitis B patients with unrecognized or untreated HIV infection.</b> Determine HIV status prior to initiating treatment with entecavir. <b>Not recommended for HIV/HBV coinfected patients unless also receiving antiretroviral therapy. </b>The manufacturer's labeling states that entecavir does not exhibit any clinically-relevant activity against human immunodeficiency virus (HIV type 1). However, a small number of case reports have indicated declines in virus levels during entecavir therapy. HIV resistance to a common HIV drug has been reported in an HIV/HBV-infected patient receiving entecavir as monotherapy for HBV.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Dose adjustment not required. Limited data supporting treatment of chronic hepatitis B in patients with decompensated liver disease; observe for increased adverse reactions, including hepatorenal dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment or patients receiving concomitant therapy which may reduce renal function; dose adjustment recommended for CrCl &lt;50 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Children: There are limited data available on the use of entecavir in lamivudine-experienced pediatric patients; use in these patients only if the potential benefit justifies the potential risk to the child.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Resistance: Cross-resistance may develop in patients failing previous therapy with lamivudine.</p></div>
<div class="block foc drugH1Div" id="F165216"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Baraclude: 0.05 mg/mL (210 mL) [contains methylparaben, propylparaben; orange flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Baraclude: 0.5 mg, 1 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg</p></div>
<div class="block geq drugH1Div" id="F165206"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F3422226"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Baraclude Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05 mg/mL (per mL): $5.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Baraclude Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $54.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $54.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Entecavir Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg (per each): $2.60 - $60.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $2.60 - $60.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866735"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Baraclude: 0.5 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg, 1 mg</p></div>
<div class="block admp drugH1Div" id="F52612693"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer on an empty stomach (2 hours before or after a meal). </p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Do not dilute or mix oral solution with water or other beverages; use calibrated oral dosing syringe.  </p></div>
<div class="block adm drugH1Div" id="F165218"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer on an empty stomach (2 hours before or after a meal). Do not dilute or mix oral solution with water or other beverages; use calibrated oral dosing syringe. Oral solution and tablet are bioequivalent on a mg-to-mg basis.</p></div>
<div class="block hazard drugH1Div" id="F49132423"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block sts drugH1Div" id="F165228"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. After opening, oral solution can be used up to expiration date on the bottle.</p></div>
<div class="block usep drugH1Div" id="F53566667"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of chronic hepatitis B infection with evidence of active viral replication and either evidence of persistent transaminase elevations or histologically active disease (FDA approved in ages ≥2 years weighing ≥10 kg and adults). <b>Note:</b> In children, indication is based on data in patients with compensated liver disease only; in adults, indication is based on data in patients with compensated and decompensated liver disease.</p></div>
<div class="block cyt drugH1Div" id="F13299265"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT2</p></div>
<div class="block dri drugH1Div" id="F3053493"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F165229"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Food delays absorption and reduces AUC by 18% to 20%. Management: Administer on an empty stomach 2 hours before or after a meal.</p></div>
<div class="block dic drugH1Div" id="F165222"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take on an empty stomach (2 hours before or after a meal).</p></div>
<div class="block rep_considerations drugH1Div" id="F57634958"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Treatment for hepatitis B should be evaluated prior to pregnancy. Entecavir is not recommended for use in pregnant patients (AASLD [Terrault 2018]; EASL 2017).</p></div>
<div class="block pri drugH1Div" id="F165221"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following maternal use of entecavir during pregnancy are available (Gao 2022; Kakiuchi 2021; Tavakolpour 2018; Yang 2022). Agents other than entecavir are recommended when hepatitis B treatment is needed in pregnant patients. Patients who become pregnant while taking entecavir should be switched to the preferred agent (AASLD [Terrault 2018]; EASL 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to entecavir are ongoing. Health care providers are encouraged to enroll patients exposed to entecavir during pregnancy in the antiretroviral pregnancy registry (1-800-258-4263).</p></div>
<div class="block mopp drugH1Div" id="F53566666"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">HIV status (prior to initiation of therapy); liver function tests, renal function; in HBV/HIV-coinfected patients, monitor HIV viral load and CD4 count; HBeAg, HBV DNA; in patients with lamivudine-refractory or -resistant viremia (or known lamivudine- or telbivudine-resistance mutations) entecavir resistance can develop rapidly. Monitor HBV DNA every 3 months (DHHS [adults], 2013).</p></div>
<div class="block pha drugH1Div" id="F165207"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Entecavir is intracellularly phosphorylated to guanosine triphosphate which competes with natural substrates to effectively inhibit hepatitis B viral polymerase; enzyme inhibition blocks reverse transcriptase activity thereby reducing viral DNA synthesis.</p></div>
<div class="block phk drugH1Div" id="F165219"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The pharmacokinetics of pediatric patients ≥2 years are similar to adult values.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Delayed with food; C<sub>max</sub> decreased 44% to 46%, AUC decreased 18% to 20%</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Extensive (V<sub>d</sub> in excess of body water)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~13%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minor hepatic glucuronide/sulfate conjugation</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tablet and oral solution are bioequivalent.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: ~5 to 6 days; accumulation: ~24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 0.5 to 1.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (60% to 73% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51154041"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Apparent oral clearance of entecavir decreased as CrCl decreased. C<sub>max</sub> and AUC increased. Hemodialysis removed about 13% of the entecavir dose over 4 hours; continuous ambulatory peritoneal dialysis (CAPD) removed about 0.3% of the dose during 7 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC was 29.3% greater in elderly subjects, most likely because of differences in renal function. Base dose adjustment of entecavir on renal function of patient, not on age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F4301433"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entriliv | Hepavir</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">B cavir</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir accord | Entecavir hcs | Entecavir mylan | Entecavir ratiopharm</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo entecavir | Baraclude | Entac | Entecavir amneal | Entecavir gh | Entecavir mylan | Entecavir rbx | Entecavir sandoz | Enteclude</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Antavir | Barcavir | Cavir | Caviral | Entavir | Enviral | Replivir | Tecavir</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir krka</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir | Entecavir accord | Entecavir alvogen</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir | Entecavir monoidratado</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir mepha | Entecavir mylan | Entecavir sandoz</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Cavigard</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Benvir</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Bo lu ding | Run zhong | Tian ding</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Catevir | Entecavir | Kalvir | Vorix | Zentair</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir accord | Entecavir aurovitas | Entecavir auxilto | Entecavir avmc | Entecavir glenmark | Entecavir mylan | Entecavir sandoz | Entecavir xantis</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir accord | Entecavir al | Entecavir amarox | Entecavir aristo | Entecavir axiromed | Entecavir beta | Entecavir cipla | Entecavir glenmark | Entecavir hec pharm | Entecavir heumann | Entecavir hexal | Entecavir klinge | Entecavir medicopharm | Entecavir mylan | Entecavir puren | Entecavir ratiopharm | Entecavir zentiva</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Baraclude</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Caviclude | Hepaclude | Tecavir</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Entecavir accord | Entecavir aristo | Entecavir aurovitas | Entecavir Dr. Reddy's | Entecavir glenmark | Entecavir kabi | Entecavir kern pharma | Entecavir mylan | Entecavir normon | Entecavir sandoz | Entecavir stada | Entecavir tarbis | Entecavir teva</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir accord | Entecavir mylan | Entecavir stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir accord | Entecavir arrow | Entecavir biogaran | Entecavir cristers | Entecavir eg | Entecavir hcs | Entecavir mylan | Entecavir ReddyPharma | Entecavir sandoz | Entecavir teva | Entecavir zentiva | Entecavir zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir | Entecavir aristo | Entecavir cipla | Entecavir Dr. Reddy's | Entecavir glenmark | Entecavir milpharm | Entecavir mylan | Entecavir zentiva</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir accord | Entecavir/sandoz | Entecavir/vocate | Istergan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Entecavir sandoz | Hepaclude | Hepavance | Hovid entecavir | Pms entecavir</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Entecavir mylan</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir alvogen | Entecavir mylan | Entecavir teva | Entekavir onkogen</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Atevir</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir | Entecavir mylan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Cronivir | Encure | Entaliv | Entavir | Enteca | Entehep | Hepalo | X vir</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir accord | Entecavir age | Entecavir aurobindo | Entecavir doc | Entecavir Dr. Reddy's | Entecavir kabi | Entecavir mylan | Entecavir sandoz | Entecavir sun | Entecavir teva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Baraclude</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir cmx | Entecavir dsep | Entecavir ee | Entecavir jg | Entecavir kn | Entecavir pfizer | Entecavir sandoz | Entecavir takata | Entecavir takeda teva | Entecavir towa | Entecavir yd</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Hepwin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Antavil | Arliclude | Bacavir | Balude | Baracavir | Baracle | Baraclude | Baracr | Baracross | Baracure | Baraenter | Baraliver | Baranuvo | Baratis | Baroad | Barud | Beyquer | Caren | Cavir | Caviran | Ceviran | Dong a pharm entecavir | Encalude | Encaron | Encavir | Encavis | Enclude | Enped | Enrud | Entai | Enteca | Entecabell | Entecare | Entecaro | Entecavir bkw | Enteclude | Entegen | Entekhan | Entekim | Enteone | Entequal | Entere | Entevir | Envir | Gcp entecavir | Heclu | Ilaclude | Ilacrude | Inist entecavir | Livarus | Prime entecavir | Riqvir | Solid | Winbarac</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Hepavir</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir biogaran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Entecavir accord | Entecavir glenmark | Hednavir</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Baraclude</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Baraclude</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Opavir</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Baraclude</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Enteca | Entecavir sandoz | Entecavir stella | Hepuri F.C. | Hovid entecavir | Tecavir</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir aurobindo | Entecavir CF | Entecavir glenmark | Entecavir mylan | Entecavir sandoz | Entecavir teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir accord | Entecavir mylan | Entecavir sandoz</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir mylan | Entecavir sandoz</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Baracross | Entegard</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Atrivir | Avir | B off | Bvir | Cavira | Centaurus | Cure b | Ecavir | Encav | Ensipasvir | Enta b | Entec | Enteca | Entevir | Envir | Eteva | Evicar | Gitver | H caver | Lenvir | Livosec c | Medcavir | Novir | Theracavir | Veer | Virastep | Virenta | Virunix b | Xotivir</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir accord | Entecavir alvogen | Entecavir aurovitas | Entecavir glenmark | Entecavir mylan | Entecavir polpharm | Entecavir sandoz | Entecavir stada | Entecavir Synoptis | Entecavir teva | Entecavir zentiva | Entekavir Adamed</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Baraclude</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Entecavir | Entecavir accord | Entecavir kabi | Entecavir mylan | Entecavir teva</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Apo-Entecavir | Baraclude | Entriliv</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir accord | Entecavir alvogen | Entecavir aurobindo | Entecavir Dr. Reddy's | Entecavir glenmark | Entecavir krka | Entecavir mylan | Entecavir sandoz | Entecavir sanience | Entecavir terapia | Entecavir teva | Entecavir zentiva | Viren</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Elgravir | Entecavir sandoz | Entecavir stada | Entecavir sun | Entecavir sz</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Elive | Hepatab | Hepavir | Pms entecavir | Tecaben</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir accord | Entecavir glenmark | Entecavir Medical Valley | Entecavir mylan | Entecavir sandoz | Entecavir stada | Entecavir teva | Entekavir Ebb</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Entecavir sandoz</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir accord | Entekavir krka | Entekavir sandoz | Entekavir stada | Entekavir teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Entecavir xantis</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Encavir | Orata</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Enebra</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Aviravir | Baravir | Fortevir | Hednavir | Hepagard | Hepatovir b | Quantavir | Viratit | Virente | Zenticavir</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Baraclude | Baravir | Besano FC | Bocanon | Entecavir sandoz | Hepato ease | Hepuri | Hepwin | Livepro | Tecavir</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ertivix | Tecavir | Zentair | Zyvir</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Amperison | Asmenide | Entecavir stada | Nulesavir</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Baraclude</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-HazDrugs.1">
<a name="HazDrugs.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Auro-Entecavir.1">
<a name="Auro-Entecavir.1"></a>Auro-Entecavir (entecavir) [product monograph]. Woodbridge, Ontario, Canada: Auro Pharma Inc, November 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baraclude.1">
<a name="Baraclude.1"></a>Baraclude (entecavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BaracludeCan.1">
<a name="BaracludeCan.1"></a>Baraclude (entecavir) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23522150">
<a name="23522150"></a>Chen FW, Coyle L, Jones BE, Pattullo V. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. <i>Liver Int</i>. 2013;33(8):1203-1210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/23522150/pubmed" id="23522150" target="_blank">23522150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22688509">
<a name="22688509"></a>Chu M, Cho SM, Choe B, et al. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55:648-652.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/22688509/pubmed" id="22688509" target="_blank">22688509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DHHS.1">
<a name="DHHS.1"></a>DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821196/" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821196/</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26454123">
<a name="26454123"></a>Dionne-Odom J, Tita AT, Silverman NS; Society for Maternal-Fetal Medicine (SMFM). SMFM Consult Series: #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. <i>Am J Obstet Gynecol.</i> 2016;214(1):6-14. doi:10.1016/j.ajog.2015.09.100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/26454123/pubmed" id="26454123" target="_blank">26454123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28427875">
<a name="28427875"></a>European Association for the Study of the Liver (EASL). EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. <i>J Hepatol</i>. 2017;67(2):370-398. doi:10.1016/j.jhep.2017.03.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/28427875/pubmed" id="28427875" target="_blank">28427875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21762659">
<a name="21762659"></a>Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. <i>Gastroenterology</i>. 2011;141(4):1212-1219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/21762659/pubmed" id="21762659" target="_blank">21762659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28370215">
<a name="28370215"></a>Fung J, Wong T, Chok K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years. <i>Hepatology</i>. 2017;66(4):1036-1044.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/28370215/pubmed" id="28370215" target="_blank">28370215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32019360">
<a name="32019360"></a>Gao X, Duan X, Cai H, et al. Pregnancy outcomes for pregnant women with chronic hepatitis B exposing to entecavir or adefovir dipivoxil therapy before or in early pregnancy. <i>J Matern Fetal Neonatal Med</i>. 2022;35(3):476-480. doi:10.1080/14767058.2020.1723540<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/32019360/pubmed" id="32019360" target="_blank">32019360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25514302">
<a name="25514302"></a>Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. <i>JAMA</i>. 2014;312(23):2521-2530.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/25514302/pubmed" id="25514302" target="_blank">25514302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20890947">
<a name="20890947"></a>Jonas MM, Block JM, Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. <i>Hepatology</i>. 2010;52(6):2192-2205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/20890947/pubmed" id="20890947" target="_blank">20890947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33768929">
<a name="33768929"></a>Kakiuchi T, Takahashi H, Iwane S, Koji A, Matsuo M. Entecavir administration to pregnant Japanese woman with chronic hepatitis B and hepatocellular carcinoma: a case report. <i>Clin Case Rep</i>. 2021;9(3):1752-1758. doi:10.1002/ccr3.3896<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/33768929/pubmed" id="33768929" target="_blank">33768929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21054683">
<a name="21054683"></a>Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. <i>J Viral Hepat</i>. 2011;18(12):877-883.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/21054683/pubmed" id="21054683" target="_blank">21054683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19714720">
<a name="19714720"></a>Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. <i>Hepatology</i>. 2009;50(3):661-662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/19714720/pubmed" id="19714720" target="_blank">19714720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22020173">
<a name="22020173"></a>Muqit MK, Stanga PE, Vilar FJ, et al. Presumed entecavir-induced ocular toxicity. <i>Eye (Lond)</i>. 2011;25(12):1665-1668.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/22020173/pubmed" id="22020173" target="_blank">22020173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21796345">
<a name="21796345"></a>Pawlowska M, Halota W, Smukalska E, et al. HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B. <i>Eur J Clin Microbiol Infect Dis</i>. 2012;31:571-574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/21796345/pubmed" id="21796345" target="_blank">21796345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23788462">
<a name="23788462"></a>Perrillo R, Buti M, Durand F, et al. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. <i>Liver Transplant</i>. 2013;19:887-895.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/23788462/pubmed" id="23788462" target="_blank">23788462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25447852">
<a name="25447852"></a>Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. <i>Gastroenterology</i>. 2015;148(1):221-244.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/25447852/pubmed" id="25447852" target="_blank">25447852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31260579">
<a name="31260579"></a>Suzuki K, Suda G, Yamamoto Y, et al; NORTE Study Group. Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. <i>Hepatol Res</i>. 2019;49(11):1294-1304. doi:10.1111/hepr.13399<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/31260579/pubmed" id="31260579" target="_blank">31260579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29020844">
<a name="29020844"></a>Tavakolpour S, Darvishi M, Mirsafaei HS, Ghasemiadl M. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review. <i>Infect Dis (Lond)</i>. 2018;50(2):95-106. doi:10.1080/23744235.2017.1384957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/29020844/pubmed" id="29020844" target="_blank">29020844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29405329">
<a name="29405329"></a>Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <i>Hepatology</i>. 2018;67(4):1560-1599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/29405329/pubmed" id="29405329" target="_blank">29405329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26225396">
<a name="26225396"></a>World Health Organization (WHO). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. https://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/. Published 2015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/26225396/pubmed" id="26225396" target="_blank">26225396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35046808">
<a name="35046808"></a>Yang R, Yin N, Zhao Y, et al. Adverse events during pregnancy associated with entecavir and adefovir: new insights from a real-world analysis of cases reported to FDA Adverse Event Reporting System. <i>Front Pharmacol</i>. Published online January 3, 2022. doi:10.3389/fphar.2021.772768<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/35046808/pubmed" id="35046808" target="_blank">35046808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27450506">
<a name="27450506"></a>Yu S, Luo H, Pan M, et al. Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. <i>Int J Clin Pharm</i>. 2016;38(5):1035-1043.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/27450506/pubmed" id="27450506" target="_blank">27450506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27121321">
<a name="27121321"></a>Zhang MY, Zhu GQ, Shi KQ, et al. Systematic review with network meta-analysis: comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. <i>Oncotarget</i>. 2016;7(21):30642-30658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/entecavir-pediatric-drug-information/abstract-text/27121321/pubmed" id="27121321" target="_blank">27121321</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 93384 Version 207.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
